<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997837</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-2021-63-2366</org_study_id>
    <nct_id>NCT04997837</nct_id>
  </id_info>
  <brief_title>Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma</brief_title>
  <official_title>A Multicenter, Randomized, Controlled Phase III Study of Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy as Adjuvant Regimen for D2/R0 Resected pN3 Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of postoperative adjuvant&#xD;
      chemotherapy with PD-1 inhibitors and chemoradiotherapy, in comparison with adjuvant&#xD;
      chemotherapy only, in D2/R0 resected pN3 gastric or gastroesophageal junction adenocarcinoma.&#xD;
      PD-1+CRT cohort: A total of 216 patients will receive 6 weeks of PD-1 inhibitors and&#xD;
      chemotherapy, then receive concurrent chemoradiotherapy, followed by 6 weeks of PD-1&#xD;
      inhibitors and chemotherapy, finally receive maintenance treatment of PD-1 inhibitors until&#xD;
      (maximum 1year after radiotherapy). CT cohort: A total of 217 patients will receive 6 months&#xD;
      of chemotherapy. The disease-free survival(DFS), overall survival(OS) and adverse effects&#xD;
      will be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">October 21, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 21, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year DFS rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the time from randomization to the date of first documented progression or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year OS rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year local recurrence free survival rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the time from randomization to the date of first documented recurrence or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with treatment-related acute adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Up to 28 days from last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by Quality of Life Scale (range 0-60)</measure>
    <time_frame>Through study completion, up to 10 years</time_frame>
    <description>It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">433</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>PD-1 inhibitor and chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-1 inhibitor+CapeOX/SOX/FOLFOX for 6 weeks, followed by chemoradiotherapy; 6 weeks of PD-1 inhibitor and CapeOX/SOX/FOLFOX for 6 weeks after chemoradiotherapy, followed by PD-1 inhibitor, till 12 months after chemoradiotherapy.&#xD;
PD-1 inhibitor Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.&#xD;
Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.&#xD;
Chemoradiotherapy Radiotherapy: 1.8 Gy/fx, 45-50.5Gy Chemotherapy: Capecitabine 625mg/m2 bid orally with radiotherapy; OR Tegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.&#xD;
CapeOX:&#xD;
Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.&#xD;
Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.&#xD;
SOX:&#xD;
Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.&#xD;
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off.&#xD;
FOLFOX:&#xD;
Oxaliplatin 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.&#xD;
5-FU 2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 inhibitor</intervention_name>
    <description>Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.</description>
    <arm_group_label>PD-1 inhibitor and chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.&#xD;
FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>PD-1 inhibitor and chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>PD-1 inhibitor and chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur-gimeracil-oteracil potassium</intervention_name>
    <description>SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>PD-1 inhibitor and chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>FOLFOXï¼š2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>PD-1 inhibitor and chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>1.8 Gy/Fx, 45-50.4 Gy</description>
    <arm_group_label>PD-1 inhibitor and chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy</description>
    <arm_group_label>PD-1 inhibitor and chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1&#xD;
&#xD;
          -  Patients with expected survival time more than 6 months&#xD;
&#xD;
          -  Patients after standard D2/R0 resection&#xD;
&#xD;
          -  Postoperative histologically confirmed adenocarcinoma of the stomach or GEJ&#xD;
&#xD;
          -  Positive lymph nodes more than 7, stage pN3&#xD;
&#xD;
          -  Patients without distant metastasis (M0) or M1 with abdominal exfoliated cell&#xD;
             detection positive (CY1P0)&#xD;
&#xD;
          -  Patients' physical condition and visceral function allows following adjuvant therapy,&#xD;
             including chemotherapy, chemoradiotherapy and PD-1 inhibitor therapy.&#xD;
&#xD;
          -  Patients' blood routine and biochemical indicators should meet the following standard:&#xD;
             Hbâ‰¥90g/L, ANCâ‰¥1.5*10^9/L, PLTâ‰¥100*10^9/L, ALT &amp; ASTâ‰¤2.5 U/L, TB â‰¤ 1.5 UNL, serum&#xD;
             creatinine&lt;1 UNL.&#xD;
&#xD;
          -  Patients who are willing to obey regimens during the study.&#xD;
&#xD;
          -  Written informed consent is acquired before random entry, and patients should know&#xD;
             that he/she has the right to quit, and following treatment won't be affected.&#xD;
&#xD;
          -  Patients are willing to provide samples of blood and tissue.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with gross peritoneal metastasis (CY1P0 excluded) or distant metastasis.&#xD;
&#xD;
          -  Patients who has received any anti-tumor therapy before surgery.&#xD;
&#xD;
          -  Patients who had received radiotherapy for abdominal organs including stomach, liver,&#xD;
             kidney, etc.&#xD;
&#xD;
          -  Patients who had active systematic autoimmune diseases which need systematic treatment&#xD;
             within 2 years before first medication in the study, substitutive therapy (such as&#xD;
             thyroxine, insulin, etc) excluded.&#xD;
&#xD;
          -  Patients diagnosed with immunodeficiency, or was receiving systematic glucocorticoid&#xD;
             treatment or other immunosuppressive therapy within 7 days before medication,&#xD;
             physiological dose of glucocorticoid is allowed (â‰¤10 mg/d prednison or equivalent&#xD;
             medication)&#xD;
&#xD;
          -  Patients who have known severe allergic reaction (â‰¥level 3) to anti-PD-1 monoclonal&#xD;
             antibody, 5-FU, Oxaliplatin or any auxiliary material.&#xD;
&#xD;
          -  Patient diagnosed with other malignant tumor in the past 5 years, excluding radical&#xD;
             basal cell carcinoma of the skin and/or radical resected carcinoma in situ.&#xD;
&#xD;
          -  Patient with severe vital organ failure.&#xD;
&#xD;
          -  Pregnant or lactation period&#xD;
&#xD;
          -  Patient with known mental illness or drug abuse that may influence compliance.&#xD;
&#xD;
          -  Patient with known HIV infection, or active tuberculosis.&#xD;
&#xD;
          -  Untreated active hepatitis B&#xD;
&#xD;
          -  Patient with active HCV infection&#xD;
&#xD;
          -  Uncontrolled complications&#xD;
&#xD;
          -  Other situations that might disturb study results and compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Zhang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhen Zhang, MD, PhD</last_name>
    <phone>18801735029</phone>
    <email>zhen_zhang@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Zhang, MD, PhD</last_name>
      <phone>18801735029</phone>
      <email>zhen_zhang@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Tegafur</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

